Study S001227

Semaglutide Treatment for PRevention Of Toxicity in High-dose Chemotherapy With Autologous Haematopoietic Stem Cell Transplantation

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06449625
Acronym: PROTECT
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: QUADRUPLE
Status: NOT_YET_RECRUITING
Enrollment: 40
Start: 2024-08-12
Primary completion: 2026-12-31
Lead sponsor: Klaus Gottlob Müller
Conditions: Intestinal Mucositis; Inflammation; Chemotherapeutic Toxicity
Interventions: DRUG:Semaglutide Pen Injector [Ozempic]; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: NO
Secondary identifiers: CTIS:2022-502139-20-00

Registered primary outcomes

gastrointestinal mucositis severity [from day of stem cell infusion (day 0) to week +3]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0011037	Semaglutide treatment for PRevention Of Toxicity in high-dosE Chemotherapy with autologous haematopoietic stem-cell Transplantation (PROTECT): study protocol for a randomised, double-blind, placebo-controlled, investigator-initiated study. Sørum ME, BMJ open	2024	Protocol	PMID 39384243 DOI	cites ClinicalTrials.gov:NCT06449625; cites CTIS:2022-502139-20-00; registry reference DERIVED:39384243